PTC Therapeutics (PTCT) volatility comes in on Serepta approval

PTC Therapeutics (NASDAQ: PTCT) whose Translarna drug seeks to treat nonsense mutation Duchenne muscular dystrophy is recently up 23%, after the FDA granted accelerated approval to Sarepta's (SRPT) eteplirsen, the company's treatment of Duchenne muscular dystrophy. PTCT October call option implied volatility is at 95, November is at 105; compared to its 52-week range of 88 to 330.

You May Also Be Interested In

• PENN Entertainment (PENN) call put ratio 10 calls to 1 put with focus on April weekly 19.50 calls
• T-Mobile (TMUS) April weekly option implied volatility into quarter results
• Union Pacific (UNP) call put ratio 1 call to 3.4 puts into quarter results